A phase I study of pegylated interferon alfa-2b as an adjuvant therapy in Japanese patients with malignant melanoma

被引：0
|
作者：
Yoshikawa, S. [1 ]
Kiyohara, Y. [1 ]
Uhara, H. [2 ]
Wada, H. [3 ]
Matsuda, K. [4 ]
Yamamoto, K. [4 ]
Shimamoto, T. [4 ]
Yamazaki, N. [5 ]
机构：
[1] Shizuoka Canc Ctr, Dermatol, Shizuoka, Japan
[2] Shinshu Univ, Sch Med, Dermatol, Matsumoto, Nagano 390, Japan
[3] Yokohama City Univ Med, Dermatol, Yokohama, Kanagawa, Japan
[4] MSD KK, Oncol Sci Unit, Tokyo, Japan
[5] Natl Canc Ctr, Dermatol Oncol, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
345PD
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [1] Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma
    Yamazaki, Naoya
    Uhara, Hisashi
    Wada, Hidefumi
    Matsuda, Kenji
    Yamamoto, Keiko
    Shimamoto, Takashi
    Kiyohara, Yoshio
    [J]. JOURNAL OF DERMATOLOGY, 2016, 43 (10): : 1146 - 1153
  • [2] Stage III melanoma and pegylated interferon alfa-2b therapy
    不详
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2008, 7 (08) : 809 - 809
  • [3] Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?
    Sondak, Vernon K.
    Flaherty, Lawrence E.
    [J]. LANCET, 2008, 372 (9633): : 89 - 90
  • [4] Pegylated interferon alfa-2b treatment for patients with solid tumors: A phase I/II study
    Bukowski, R
    Ernstoff, MS
    Gore, ME
    Nemunaitis, JJ
    Amato, R
    Gupta, SK
    Tendler, CL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) : 3841 - 3849
  • [5] Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
    Davar, Diwakar
    Wang, Hong
    Chauvin, Joe-Marc
    Pagliano, Ornella
    Fourcade, Julien J.
    Ka, Mignane
    Menna, Carmine
    Rose, Amy
    Sander, Cindy
    Borhani, Amir A.
    Karunamurthy, Arivarasan
    Tarhini, Ahmad A.
    Tawbi, Hussein A.
    Zhao, Qing
    Moreno, Blanca H.
    Ebbinghaus, Scott
    Ibrahim, Nageatte
    Kirkwood, John M.
    Zarour, Hassane M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (35) : 3450 - +
  • [6] Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma
    Jia, Dong-Dong
    Niu, Yanling
    Zhu, Honglin
    Wang, Sizhen
    Ma, Tonghui
    Li, Tao
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [7] Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma
    Lohmann, CP
    Kroher, G
    Bogenrieder, T
    Spiegel, D
    Preuner, J
    [J]. LANCET, 1999, 353 (9161): : 1326 - 1326
  • [8] Thyrotoxicosis With Pegylated Interferon Alfa-2b
    Lowndes, Sarah A.
    Asher, Ruth
    Middleton, Mark R.
    [J]. ARCHIVES OF DERMATOLOGY, 2010, 146 (11) : 1273 - 1275
  • [9] Adjuvant interferon alfa-2b for high-risk melanoma
    Retsas, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) : 1968 - 1968
  • [10] Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C
    Jen, JF
    Glue, P
    Ezzet, F
    Chung, C
    Gupta, SK
    Jacobs, S
    Hajian, G
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (06) : 407 - 421
12345